Published

2025-03-17

An analytical of an experimental method for evaluation and validation from measuring dissolution of Metformin and Empagliflozin for generic tablets: Confirmation the results by docking method

Análisis de un método experimental para la evaluación y validación de la medición de la disolución de metformina y empagliflozina en comprimidos genéricos: confirmación de los resultados mediante el método de acoplamiento

Uma análise de um método experimental para avaliação e validação da medição da dissolução de Metformina e Empagliflozina para comprimidos genéricos: Confirmação dos resultados pelo método de encaixe

DOI:

https://doi.org/10.15446/rcciquifa.v53n3.119242

Keywords:

Metformin, Empagliflozin, type 2 diabetes, HPLC, glycaemia control, docking simulation, molecular dynamic, drug design (en)
metformina, empagliflozina, diabetes tipo 2, HPLC, control de la glucemia, simulación de acoplamiento, dinámica molecular, diseño de fármacos (es)
metformina, empagliflozina, diabetes tipo 2, HPLC, controle da glicemia, simulação de encaixe, dinâmica molecular, design de fármacos (pt)

Downloads

Authors

  • Motahareh Dehghandar Department of Chemical engineering, Science and Research branch, Islamic Azad University, Tehran, Iran
  • Parisa Latifi Department of Pharmaceutics, Faculty of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
  • Sara Shahriari Department of Chemistry, Central Tehran Branch, Islamic Azad University, Tehran, Iran
  • Fatemeh Mollaamin Department of Biomedical Engineering, Faculty of Engineering and Architecture, Kastamonu University, Kastamonu, Turkey
  • Iman Eskandary Department of Chemistry, Payame Noor University, Mazandaran, Sari, Iran
  • Majid Monajjemi Departments of Chemical Engineering, Central Tehran Branch, Islamic Azad University, Tehran, Iran

Aim: Validation for assay and dissolution of metformin and Empagliflozin in tablet 500:5 mg for evaluating the efficacy and safety of linagliptin vs. placebo in patients with type 2 diabetes. Materials and methods: The HPLC system used was Shimadzu LC-2010 HT with UV detector and Empagliflozin standard stock 1: 28 mg of Empagliflozin was accurately prepared. Separately 10 μL of standard solution and sample solution was injected into the chromatographic system. Patients with inadequate glycaemia control despite stable-dose metformin received open-label Empagliflozin as add-on therapy for several weeks. All patients continued treatment with metformin and Empagliflozin or metformin and Empagliflozin. The primary endpoint was change from baseline. Results: The experiments were significantly exhibited a reducing the problem in patients with type 2 diabetes. In addition, results of docking method confirmed also the effectiveness of Metformin/ Empagliflozin tablets to better controlling of diabete-type-2 disease. Conclusions: Empagliflozin in Metformin/Empagliflozin for 24 weeks improved glycaemia control and was well tolerated.

Objetivo: Validación del ensayo y disolución de metformina y empagliflozina en comprimidos de 500:5 mg para evaluar la eficacia y seguridad de la linagliptina frente a placebo en pacientes con diabetes tipo 2. Materiales y métodos: El sistema HPLC utilizado fue Shimadzu LC-2010 HT con detector UV y para la solución madre estándar de empagliflozina 1: se prepararon con precisión 28 mg de empagliflozina. Se inyectaron por separado 10 μL de solución estándar y la solución de muestra en el sistema cromatográfico. Los pacientes con un control inadecuado de la glucemia a pesar de la administración de metformina en dosis estables recibieron empagliflozina de etiqueta abierta como terapia complementaria durante varias semanas. Todos los pacientes continuaron el tratamiento con metformina y empagliflozina o metformina y empagliflozina. El criterio de valoración principal fue el cambio con respecto al valor inicial. Resultados: Los experimentos mostraron una reducción significativa del problema en pacientes con diabetes tipo 2. Además, los resultados del método de acoplamiento confirmaron también la eficacia de los comprimidos de metformina/empagliflozina para controlar mejor la enfermedad diabética tipo 2. Conclusiones: La empagliflozina en combinación con metformina/empagliflozina durante 24 semanas mejoró el control de la glucemia y fue bien tolerada.

Objetivo: Validação para ensaio e dissolução de metformina e Empagliflozina em comprimido 500:5 mg para avaliar a eficácia e segurança da linagliptina vs. placebo em pacientes com diabetes tipo 2. Materiais e métodos: O sistema HPLC usado foi Shimadzu LC-2010 HT com detector UV e estoque padrão de Empagliflozina 1: 28 mg de Empagliflozina foram preparados com precisão. Separadamente, 10 μL de solução padrão e solução de amostra foram injetados no sistema cromatográfico. Pacientes com controle glicêmico inadequado, apesar da metformina em dose estável, receberam Empagliflozina de rótulo aberto como terapia complementar por várias semanas. Todos os pacientes continuaram o tratamento com metformina e Empagliflozina ou metformina e Empagliflozina. O desfecho primário foi a mudança da linha de base. Resultados: Os experimentos exibiram significativamente uma redução do problema em pacientes com diabetes tipo 2. Além disso, os resultados do método de encaixe confirmaram também a eficácia dos comprimidos de Metformina/Empagliflozina para melhor controle da doença diabética tipo 2. Conclusões: A empagliflozina em Metformina/Empagliflozina por 24 semanas melhorou o controle da glicemia e foi bem tolerada.

References

1. B. Lal, D. Kapoor, M. Jaimini, A review on analytical method validation and its regulatory perspectives, Journal of Drug Delivery and Therapeutics, 9(2), 501-566 (2019). Doi: https://doi.org/10.22270/jddt.v9i2.2403

2. O. Gassmann, G. Reepmeyer, M. Zedtwitz, Leading Pharmaceutical Innovation: Trends and Drivers for Growth in the Pharmaceutical Industry, 2nd ed., Springer Berlin, Heidelberg, 2008, p. 186. Doi: https://doi.org/10.1007/978-3-540-77636-9

3. J. Breaux, K. Jones, P. Boulas, Understanding and implementing efficient analytical methods development and validation, Pharmaceutical Online, 6-13 (2003). URL: https://www.bioprocessonline.com/doc/understanding-andimplementing-efficient-anal-0001

4. M. Monajjemi, F. Mollaamin, S. Shojaei, An overview on coronaviruses family from past to COVID-19: Introduce some inhibitors as antiviruses from Gillan’s plants, Biointerface Research in Applied Chemistry, 10(3), 5575-5585 (2020). Doi: https://doi.org/10.33263/BRIAC103.575585

5. B. Khalili-Hadad, F. Mollaamin, M. Monajjemi, Biophysical chemistry of macrocycles for drug delivery: A theoretical study, Russian Chemical Bulletin, 60(2), 238-241 (2011). Doi: https://doi.org/10.1007/s11172-011-0039-5

6. P. Ravisankar, C.N. Navya, D. Pravallika, D.N. Sri, A review on step-by-step analytical method validation, IOSR Journal of Pharmacy, 5(10), 7-19 (2015). URL: http://www.iosrphr.org/papers/v5i10/B051007019.pdf

7. T. Pranshu, R.P. Singh, J. Vikash, Lakshmayya, Validation: A critical parameter for quality control of pharmaceuticals, Journal of Drug Delivery and Therapeutics, 2(3), 34-40 (2012). Doi: https://doi.org/10.22270/jddt.v2i3.151

8. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A.L. Peters, A. Tsapas, R. Wender, D.R. Matthews, Management of hyperglycemia in type 2 diabetes: a patient centered approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetes Care, 35(6), 1364-1379 (2012). Doi: https://doi.org/10.2337/dc12-0413

9. S.E. Kahn, S.M. Haffner, M.A. Heise, W.H. Herman, R.R. Holman, N.P. Jones, B.G. Kravitz, J.M. Lachin, M.C. O’Neill, B. Zinman, G. Viberti, ADOPT Study Group, Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy, The New England Journal of Medicine, 355(23), 2427-2443 (2006). Doi: https://doi.org/10.1056/NEJMoa066224

10. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A.L. Peters, A. Tsapas, R. Wender, D.R. Matthews, Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, 38(1), 140-149 (2015). Doi: https://doi.org/10.2337/dc14-2441

11. L.A. Gallo, E.M. Wright, V. Vallon, Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences, Diabetes and Vascular Disease Research, 12(2), 78-89 (2015). Doi: https://doi.org/10.1177/1479164114561992

12. H.-U. Häring, L. Merker, E. Seewaldt-Becker, M. Weimer, T. Meinicke, U.C. Broedl, H.J. Woerle, Empagliflozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial, Diabetes Care, 37(6), 1650-1659 (2014). Doi: https://doi.org/10.2337/dc13-2105

13. L. Merker, H.-U. Häring, A. V. Christiansen, F. Roux, A. Salsali, G. Kim, T. Meinicke, H.J. Woerle, U.C. Broedl, Empagliflozin as add-on to metformin in people with type 2 diabetes, Diabetic Medicine, 32(12), 1555-1567 (2015). Doi: https://doi.org/10.1111/dme.12814

14. L. Thomas, M. Eckhardt, E. Langkopf, M.Tadayyon, F. Himmelsbach, M. Mark, (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors, The Journal of Pharmacology and Experimental Therapeutics, 325(1), 175-182 (2008). Doi: https://doi.org/10.1124/jpet.107.135723

15. C.F. Deacon, Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus, Nature Reviews Endocrinology, 16(11), 642-653 (2020). Doi: https://doi.org/10.1038/s41574-020-0399-8

16. D.R. Owens, R. Swallow, K.A. Dugi, H.J. Woerle, Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: A 24-week randomized study, Diabetic Medicine, 28(11), 1352-1361 (2011). Doi: https://doi.org/10.1111/j.1464-5491.2011.03387.x

17. F. Mollaamin, M. Monajjemi, In situ drug delivery investigation through characterization and application of carbon-based nanomaterials: A promising approach for treating viral diseases, Journal of Biological Regulators and Homeostatic Agents, 38(3), 1961-1973 (2024). Doi: https://doi.org/10.23812/j.biol.regul.homeost.agents.20243803.153

18. F. Mollaamin, M. Monajjemi, A.R. Alsayed, Physico-chemical study of the antidiabetic drug of [BzN-EJJ-amide] for treatment type 2 diabetes using CNT sensor by drug delivery method, OBM Genetics, 8(2), 245 (2024). Doi: https://doi.org/10.21926/obm.genet.2402245

19. F. Mollaamin, M. Monajjemi, Drug delivery using doping of boron nitride nanosensor towards releasing chloroquine drug in the cells: A promising method for overcoming viral disease, Revista Colombiana de Ciencias Químico-Farmacéuticas, 53(2), 430-454 (2024). Doi. https://doi.org/10.15446/rcciquifa.v53n2.114450

20. F. Mollaamin, S. Shahriari, M. Monajjemi, Therapeutic role of medicinal plants against viral diseases focusing on COVID-19: Application of computational chemistry towards drug design, Revista Colombiana de Ciencias Químico-Farmacéuticas, 53(1), 19-43 (2024). Doi: https://doi.org/10.15446/rcciquifa.v53n1.112978

21. F. Mollaamin, S. Shahriari, M. Monajjemi, Monkeypox disease treatment by tecovirimat adsorbed onto single-walled carbon nanotube through drug delivery method, Journal of the Chilean Chemical Society, 68(1), 5796-5801 (2023). Doi: https://doi.org/10.4067/S0717-97072023000105796

22. F. Mollaamin, Structural and functional characterization of medicinal plants as selective antibodies towards therapy of COVID-19 symptoms, Antibodies (Basel), 13(2), 38 (2024). Doi: https://doi.org/10.3390/antib13020038

23. M. Bajaj, R. Gilman, S. Patel, J. Kempthorne-Rawson, D. Lewis-D’Agostino, H.J. Woerle, Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, doubleblind study, Diabetic Medicine, 31(12), 1505-1514(2014). Doi: https://doi.org/10.1111/dme.12495

24. E. Marrett, T. Stargardt, P. Mavros, C.M. Alexander, Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: Associations with hypoglycaemia and weight gain, Diabetes, Obesity and Metabolism, 11(12), 1138-1144 (2009). Doi: https://doi.org/10.1111/j.1463-1326.2009.01123.x

25. X.-W. Chen, Z.-X. He, Z.-W. Zhou, T. Yang, X. Zhang, Y.-X. Yang, W. Duan, S.-F. Zhou, Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus, Clinical and Experimental Pharmacology and Physiology, 42(10), 999-1024 (2015). Doi: https://doi.org/10.1111/1440-1681.12455

26. F. Mollaamin, Characterizing the structural and physicochemical properties of medicinal plants as a proposal for treating of viral malady, Trends in Immunotherapy, 7(2), 2329 (2023). Doi: https://doi.org/10.24294/ti.v7.i2.2329

27. F. Mollaamin, S. Shahriari, M. Monajjemi, Treating omicron BA.4 & BA.5 via herbal antioxidant asafoetida: A DFT study of carbon nanocarrier in drug delivery, Journal of the Chilean Chemical Society, 68(1), 5781-5786 (2023). Doi: https://doi.org/10.4067/S0717-97072023000105781

28. F. Mollaamin, Computational methods in the drug delivery of carbon nanocarriers onto several compounds in Sarraceniaceae medicinal plant as monkeypox therapy, Computation, 11(4), 84 (2023). Doi: https://doi.org/10.3390/computation11040084

29. G. Schernthaner, A.H. Barnett, A. Emser, S. Patel, J. Troost, H.-J. Woerle, M. von Eynatten, Safety and tolerability of linagliptin: A pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus, Diabetes, Obesity and Metabolism, 14(5), 470-478 (2012). Doi: https://doi.org/10.1111/j.1463-1326.2012.01565.x

30. A.H. Barnett, Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus, Postgraduate Medicine, 125(5), 92-100 (2013). Doi: https://doi.org/10.3810/pgm.2013.09.2698

How to Cite

APA

Dehghandar, M., Latifi, P., Shahriari, S., Mollaamin, F., Eskandary, I. and Monajjemi, M. (2025). An analytical of an experimental method for evaluation and validation from measuring dissolution of Metformin and Empagliflozin for generic tablets: Confirmation the results by docking method. Revista Colombiana de Ciencias Químico-Farmacéuticas, 53(3), 905–929. https://doi.org/10.15446/rcciquifa.v53n3.119242

ACM

[1]
Dehghandar, M., Latifi, P., Shahriari, S., Mollaamin, F., Eskandary, I. and Monajjemi, M. 2025. An analytical of an experimental method for evaluation and validation from measuring dissolution of Metformin and Empagliflozin for generic tablets: Confirmation the results by docking method. Revista Colombiana de Ciencias Químico-Farmacéuticas. 53, 3 (Mar. 2025), 905–929. DOI:https://doi.org/10.15446/rcciquifa.v53n3.119242.

ACS

(1)
Dehghandar, M.; Latifi, P.; Shahriari, S.; Mollaamin, F.; Eskandary, I.; Monajjemi, M. An analytical of an experimental method for evaluation and validation from measuring dissolution of Metformin and Empagliflozin for generic tablets: Confirmation the results by docking method. Rev. Colomb. Cienc. Quím. Farm. 2025, 53, 905-929.

ABNT

DEHGHANDAR, M.; LATIFI, P.; SHAHRIARI, S.; MOLLAAMIN, F.; ESKANDARY, I.; MONAJJEMI, M. An analytical of an experimental method for evaluation and validation from measuring dissolution of Metformin and Empagliflozin for generic tablets: Confirmation the results by docking method. Revista Colombiana de Ciencias Químico-Farmacéuticas, [S. l.], v. 53, n. 3, p. 905–929, 2025. DOI: 10.15446/rcciquifa.v53n3.119242. Disponível em: https://revistas.unal.edu.co/index.php/rccquifa/article/view/119242. Acesso em: 2 apr. 2025.

Chicago

Dehghandar, Motahareh, Parisa Latifi, Sara Shahriari, Fatemeh Mollaamin, Iman Eskandary, and Majid Monajjemi. 2025. “An analytical of an experimental method for evaluation and validation from measuring dissolution of Metformin and Empagliflozin for generic tablets: Confirmation the results by docking method”. Revista Colombiana De Ciencias Químico-Farmacéuticas 53 (3):905-29. https://doi.org/10.15446/rcciquifa.v53n3.119242.

Harvard

Dehghandar, M., Latifi, P., Shahriari, S., Mollaamin, F., Eskandary, I. and Monajjemi, M. (2025) “An analytical of an experimental method for evaluation and validation from measuring dissolution of Metformin and Empagliflozin for generic tablets: Confirmation the results by docking method”, Revista Colombiana de Ciencias Químico-Farmacéuticas, 53(3), pp. 905–929. doi: 10.15446/rcciquifa.v53n3.119242.

IEEE

[1]
M. Dehghandar, P. Latifi, S. Shahriari, F. Mollaamin, I. Eskandary, and M. Monajjemi, “An analytical of an experimental method for evaluation and validation from measuring dissolution of Metformin and Empagliflozin for generic tablets: Confirmation the results by docking method”, Rev. Colomb. Cienc. Quím. Farm., vol. 53, no. 3, pp. 905–929, Mar. 2025.

MLA

Dehghandar, M., P. Latifi, S. Shahriari, F. Mollaamin, I. Eskandary, and M. Monajjemi. “An analytical of an experimental method for evaluation and validation from measuring dissolution of Metformin and Empagliflozin for generic tablets: Confirmation the results by docking method”. Revista Colombiana de Ciencias Químico-Farmacéuticas, vol. 53, no. 3, Mar. 2025, pp. 905-29, doi:10.15446/rcciquifa.v53n3.119242.

Turabian

Dehghandar, Motahareh, Parisa Latifi, Sara Shahriari, Fatemeh Mollaamin, Iman Eskandary, and Majid Monajjemi. “An analytical of an experimental method for evaluation and validation from measuring dissolution of Metformin and Empagliflozin for generic tablets: Confirmation the results by docking method”. Revista Colombiana de Ciencias Químico-Farmacéuticas 53, no. 3 (March 17, 2025): 905–929. Accessed April 2, 2025. https://revistas.unal.edu.co/index.php/rccquifa/article/view/119242.

Vancouver

1.
Dehghandar M, Latifi P, Shahriari S, Mollaamin F, Eskandary I, Monajjemi M. An analytical of an experimental method for evaluation and validation from measuring dissolution of Metformin and Empagliflozin for generic tablets: Confirmation the results by docking method. Rev. Colomb. Cienc. Quím. Farm. [Internet]. 2025 Mar. 17 [cited 2025 Apr. 2];53(3):905-29. Available from: https://revistas.unal.edu.co/index.php/rccquifa/article/view/119242

Download Citation

License

Copyright (c) 2025 Revista Colombiana de Ciencias Químico-Farmacéuticas

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The Department of Pharmacy of the Faculty of Sciences of the National University of Colombia authorizes the photocopy of articles and texts for academic or internal purposes of the institutions, citing the source. The ideas issued by the authors are the express responsibility of these and it does not necessarily reflect the views of this journal.

The entire contents of this journal, except when is identified, are subject to a Creative Commons Attribution License 4.0 adopted by Colombia. Consult the regulation: http://co.creativecommons.org/?page_id=13